Mark L. Moster
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mark L. Moster has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Catherine Vignal-Clermont
Hopital Fondation, Adolphe de Rothschild 29, rue Manin, 75019 Paris, France
2 shared publications - Magali Taiel
GenSight Biologics, Paris, France
2 shared publications - Patrick Yu-Wai-Man
Cambridge University Hospitals;University of Cambridge
2 shared publications - Robert C. Sergott
William H. Annesley Jr. EyeBrain Center, Vicky and Jack Farber Neuroscience Institute, Thomas Jefferson University, Partnered with Wills Eye Hospital, Philadelphia, PA, USA
2 shared publications - Thomas Klopstock
Department of Neurology, Friedrich-Baur-Institute, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany
2 shared publications - Valerio Carelli
Programma di Neurogenetica, IRCCS Istituto Delle Scienze Neurologiche di Bologna, 40139 Bologna, Italy
2 shared publications
Latest Publications
- Open Access
- 8 December 2022
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 249, 108-125
Safety of Lenadogene Nolparvovec Gene Therapy Over 5 Years in 189 Patients With Leber Hereditary Optic Neuropathy
- 8 December 2022
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 249, 108-125
Open AccessSafety of Lenadogene Nolparvovec Gene Therapy Over 5 Years in 189 Patients With Leber Hereditary Optic Neuropathy
- Open Access
- 23 July 2021
- Published by Wolters Kluwer Health in Journal of Neuro-Ophthalmology
- Vol. 41 (3) , 298-308
Cross-Sectional Analysis of Baseline Visual Parameters in Subjects Recruited Into the RESCUE and REVERSE ND4-LHON Gene Therapy Studies
Objective: This report presents a cross-sectional analysis of the baseline characteristics of subjects with Leber hereditary optic neuropathy enrolled in the gene therapy trials RESCUE and REVERSE, to illustrate the evolution of visual parameters over the first year after vision loss. Methods: RESCUE and REVERSE were 2 phase III clinical trials designed to assess the efficacy of rAAV2/2-ND4 gene therapy in ND4-LHON subjects. At enrollment, subjects had vision loss for ≤6 months in RESCUE, and between 6 and 12 months in REVERSE. Functional visual parameters (best-corrected visual acuity [BCVA], contrast sensitivity [CS], and Humphrey Visual Field [HVF]) and structural parameters assessed by spectral-domain optical coherence tomography were analyzed in both cohorts before treatment. The cross-sectional analysis of functional and anatomic parameters included the baseline values collected in all eyes at 2 different visits (Screening and Inclusion). Results: Seventy-six subjects were included in total, 39 in RESCUE and 37 in REVERSE. Mean BCVA was significantly worse in RESCUE subjects compared with REVERSE subjects (1.29 and 1.61 LogMAR respectively, P = 0.0029). Similarly, mean CS and HVF were significantly more impaired in REVERSE vs RESCUE subjects (P < 0.005). The cross-sectional analysis showed that the monthly decrease in BCVA, ganglion cell layer macular volume, and retinal nerve fiber layer thickness was much more pronounced in the first 6 months after onset (+0.24 LogMAR, −0.06 mm3, and −6.00 μm respectively) than between 6 and 12 months after onset (+0.02 LogMAR, −0.01 mm3, and −0.43 μm respectively). Conclusion: LHON progresses rapidly in the first months following onset during the subacute phase, followed by relative stabilization during the dynamic phase.
- 23 July 2021
- Published by Wolters Kluwer Health in Journal of Neuro-Ophthalmology
- Vol. 41 (3) , 298-308
Open AccessCross-Sectional Analysis of Baseline Visual Parameters in Subjects Recruited Into the RESCUE and REVERSE ND4-LHON Gene Therapy Studies
Objective: This report presents a cross-sectional analysis of the baseline characteristics of subjects with Leber hereditary optic neuropathy enrolled in the gene therapy trials RESCUE and REVERSE, to illustrate the evolution of visual parameters over the first year after vision loss. Methods: RESCUE and REVERSE were 2 phase III clinical trials designed to assess the efficacy of rAAV2/2-ND4 gene therapy in ND4-LHON subjects. At enrollment, subjects had vision loss for ≤6 months in RESCUE, and between 6 and 12 months in REVERSE. Functional visual parameters (best-corrected visual acuity [BCVA], contrast sensitivity [CS], and Humphrey Visual Field [HVF]) and structural parameters assessed by spectral-domain optical coherence tomography were analyzed in both cohorts before treatment. The cross-sectional analysis of functional and anatomic parameters included the baseline values collected in all eyes at 2 different visits (Screening and Inclusion). Results: Seventy-six subjects were included in total, 39 in RESCUE and 37 in REVERSE. Mean BCVA was significantly worse in RESCUE subjects compared with REVERSE subjects (1.29 and 1.61 LogMAR respectively, P = 0.0029). Similarly, mean CS and HVF were significantly more impaired in REVERSE vs RESCUE subjects (P < 0.005). The cross-sectional analysis showed that the monthly decrease in BCVA, ganglion cell layer macular volume, and retinal nerve fiber layer thickness was much more pronounced in the first 6 months after onset (+0.24 LogMAR, −0.06 mm3, and −6.00 μm respectively) than between 6 and 12 months after onset (+0.02 LogMAR, −0.01 mm3, and −0.43 μm respectively). Conclusion: LHON progresses rapidly in the first months following onset during the subacute phase, followed by relative stabilization during the dynamic phase.
- 18 April 2017
- Published by Wolters Kluwer Health in Neurology
- Vol. 88 (16_supplem)
Dalfampridine Treatment in Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) (P5.202)
- 18 April 2017
- Published by Wolters Kluwer Health in Neurology
- Vol. 88 (16_supplem)
Dalfampridine Treatment in Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) (P5.202)
- 1 January 2014
- Published by Elsevier
- p. 610
Horner's Syndrome
- 1 December 1990
- Published by American Medical Association (AMA) in Archives of Ophthalmology (1950)
- Vol. 108 (12) , 1667
The Cocaine Test and Horner's Syndrome
To the Editor. —I read with interest the article by Kardon et al1 on the use of the cocaine test in the diagnosis of Horner's syndrome. Their study supports the fact that cocaine can distinguish a patient with Horner's syndrome from a patient without. The major emphasis of their article is that the degree of physiologic anisocoria after instillation of cocaine provides a better prediction of Horner's syndrome than the actual change of anisocoria noted between the precocaine and postcocaine conditions. They note that with a 1.0-mm anisocoria after cocaine instillation, the odds of having Horner's syndrome were 5990 to 1. Although this odds ratio may be valid for their study, in which the control population had no anisocoria, I believe it may be misleading. Clinically, one rarely has to distinguish between normal pupils, as in their control patients with no anisocoria, and Horner's syndrome. In practice, one must
- 1 December 1990
- Published by American Medical Association (AMA) in Archives of Ophthalmology (1950)
- Vol. 108 (12) , 1667
The Cocaine Test and Horner's Syndrome
To the Editor. —I read with interest the article by Kardon et al1 on the use of the cocaine test in the diagnosis of Horner's syndrome. Their study supports the fact that cocaine can distinguish a patient with Horner's syndrome from a patient without. The major emphasis of their article is that the degree of physiologic anisocoria after instillation of cocaine provides a better prediction of Horner's syndrome than the actual change of anisocoria noted between the precocaine and postcocaine conditions. They note that with a 1.0-mm anisocoria after cocaine instillation, the odds of having Horner's syndrome were 5990 to 1. Although this odds ratio may be valid for their study, in which the control population had no anisocoria, I believe it may be misleading. Clinically, one rarely has to distinguish between normal pupils, as in their control patients with no anisocoria, and Horner's syndrome. In practice, one must